The following are the most common clinical features of POEMS syndrome, either symptoms or signs.

It therefore remains doubtful as to whether this will become part of standard treatment for POEMS syndrome.

It is usually the symptoms of neuropathy which prompt a person with POEMS syndrome to seek medical attention.

Some features have been observed in patients with POEMS syndrome but are not yet certain to form part of the syndrome itself.

Specific endocrine abnormalities associated with POEMS syndrome vary from case to case.

However, the specific role M-proteins play and the exact cause of POEMS syndrome is unknown.

Papilloedema is a common sign of POEMS syndrome, occurring in a significant proportion of cases.

Skin changes: A very wide variety of skin problems have been reported in association with POEMS syndrome.

POEMS syndrome is associated with a group of disorders known as monoclonal gammopathies or plasma cell dyscrasias.

The most recent criteria for the diagnosis of POEMS syndrome require that all of the following be present:

There are no randomised controlled trials of treatment in POEMS syndrome, owing to its rarity.

Myeloma is the most common plasma-cell proliferative disorder associated with POEMS syndrome, present in more than half of all cases.

Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome.

Castleman's is seen in POEMS syndrome and is implicated in 10% of cases of paraneoplastic pemphigus.

Most myelomas associated with POEMS syndrome are osteosclerotic, in contrast to the osteolytic bone lesions in most other myelomas.

M-proteins are supposed to fight foreign substances in the body such as viruses and bacteria, but researchers suspect that they play a role in the development of POEMS syndrome.

POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, or PEP syndrome) is a rare medical syndrome.

Given that VEGF plays a central role in the symptoms of POEMS syndrome, some have tried bevacizumab (Avastin), a monoclonal antibody directed against VEGF.

POEMS syndrome - the E is for endocrinopathy; the cause is a paraprotein excreted by a plasmacytoma or multiple myeloma; other features are polyneuropathy, organomegaly (hepatomegaly and splenomegaly), M-protein (paraprotein) and skin changes.

The paraprotein alone is insufficient to explain the multi-organ features, and various cytokines produced by plasmacytoma cells have therefore been linked with the features of POEMS syndrome, specifically interleukin 1β, interleukin 6 and TNFα.

According to a WPVI special report from November, 2005, Lisa finally ended up at the Mayo Clinic in Minnesota, where she got the right diagnosis: she was suffering from a syndrome called POEMS Syndrome, which can cause nerve damage, organ enlargement, hormonal imbalances, and skin changes.

Glomeruloid hemangioma is a distinctive vascular neoplasm first described in 1990 when found to be associated with Crow-Fukase syndrome and Castleman's disease.

Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome.

POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, or PEP syndrome) is a rare medical syndrome.

POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, or PEP syndrome) is a rare medical syndrome.